FDA Sends Official Warnings that Sell CBD Products with Unsubstantiated Claims

The U.S. Food and Drug Administration (FDA) sent a warning letter to Curaleaf Inc., for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases. The FDA has also sent warning letters to other companies. The FDA reiterated its monitoring of the marketplace by taking action as needed against companies that deceive consumers and put them at risk by illegally selling products marketed for therapeutic uses for which they are not approved. Andersen Sleater Sianni attorneys represent consumers who have purchased products that were not as advertised including failing to provide the benefits that they purported to have. Click here to read more about the FDA's action.